This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of myasthenia gravis along with the positive topline results from the Phase 3 VIVACITY study

Ticker(s): JNJ

Who's the expert?

Institution: North Texas Institute of Neurology, Headache 

  • Neurologist at North Texas Institute of Neurology & Headache. 
  • Manages 500 patients with myasthenia gravis
  • Special interest in patients with neuromuscular diseases (i.e., peripheral neuropathy, myopathy, myasthenia gravis, etc.) and headaches

Interview Goal
The focus of this interview will be on the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of myasthenia gravis along with the positive topline results from the Phase 3 VIVACITY study

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.